EUROPEAN JOURNAL OF BIOMEDICAL AND PHARMACEUTICAL SCIENCES
http://www.ejbps.com

ISSN 2349-8870
Volume: 9
Issue: 7
128-134
Year: 2022

# SELF-EMULSIFYING DRUG DELIVERY SYSTEM: A SYSTEMIC REVIEW

**Vaishnavi G. Vaidya*, Pravin B. Suruse, Chetna Waghale and Swati Shivankar**

Department of Pharmacy, Kamla Nehru College of Pharmacy, Butibori, Nagpur, MH, India.

***Corresponding Author: Vaishnavi G. Vaidya**
Department of Pharmacy, Kamla Nehru College of Pharmacy, Butibori, Nagpur, MH, India.

**Article Received on 05/05/2022** **Article Revised on 25/05/2022** **Article Accepted on 15/06/2022**

## ABSTRACT
Drug delivery methods based on lipids have been used to create hydrophobic pharmaceuticals, allowing us to improve via penetration membrane biologicals while also protecting active components from the harsh in-vivo environment, thereby increasing bioavailability. The current study used different ratios of surfactants, lipids, and co-surfactants to build a loaded drug in a self-emulsifying drug distribution system (SEDDS) to inhibit first-pass metabolism. The emulsification zone was calculated using a pseudo-ternary phase diagram that was created. A 35-40 % of newly introduced medications have low water solubility, resulting in poor dissolution and absorption. There is no bioavailability, as well as significant heterogeneity within and between subjects, and no dosage proportionality. The current studies provide an up-to-date overview of SEDDS advancements in structure, assessment, and multiple dosage form innovative processes liquid SEDDS. SEDDS are solid conversion solids with numerous applications. By increasing medication solubility and reducing gastrointestinal discomfort, this formulation improved bioavailability. Because over 40% of novel medicinal hydrophobic chemicals are found in nature, SEDDS research will continue, and more medicinal compounds manufactured as SEDDS will be used currently available in the market future. Furthermore, at half the dosage of medicine in SEDDS formulation, the improved formulation had revealed equal therapeutic effectiveness (anti-hypertensive) to the advertised tablet.

**KEYWORDS:** Isotropic emulsions, Bioavailability, Medication delivery that self-emulsifies systems.

## INTRODUCTION
Drug delivery methods that self-emulsify (SEDDS) have been popular throughout the last few years as a strategy to boost poorly absorbed nutrients' oral bioavailability substances drugs soluble medicines in water, such as herbal products or their phytoconstituents. An isotropic oil, surfactant, and other ingredients co-surfactant/co-solvent applied during this type of lipid-based formulation.

When SEDDS become acquainted with stomach juices, they produce homogeneous, thermodynamically stable nano emulsions (o/w). SEDDS offers several advantages over other lipid-based delivery systems. It protects the drug or active ingredient from the intestinal environment (GIT), inhibits P-glycoprotein-mediated drug efflux and first-pass gut metabolism, increases permeability and lymphatic transport, improves drug plasma concentration profile control, and improves effectiveness of medication loading and stability. With slight agitation generated by stomach motility, these systems create fine emulsions (or micro-emulsions) in the stomach intestines (GIT). Oil/surfactant ratio, surfactant concentration droplet polarity, emulsion polarity size, and charge are all important factors in oral medication absorption from SEEDS. The utilization of SEDDS in the elaboration of peptide-protein pharmaceuticals to solve in vivo stability issues stems from the formulations' protective action against enzymes across stomach and intestines Characterization experiments were completed with the goal of improving formulation parameters and assess the permeation-enhancing impact of these new formulations.

However, self-organizing systems frequently contribute to an improvement in the clinical index of lipophilic medicines through increased solubilization and changes in pharmacokinetic profiles. Recent research provides an up-to-date overview of SEDDS improvements in terms of structure, assessment, multiple and dosage forms, and innovative liquid SEDDS processes. SEDDS that are solid-solid have a wide range of applications.

Different approaches, such as salt creation, solid dispersion, and complex formation, can help to improve this. Compounds for increasing the solubility of lipophilic substances. The excipients used in the development of SEDDS formulations not only allow for the creation of weakly water-soluble pharmacological molecules, but they also have an impact on the medication's intestinal permeability.[4]




**Fig. no. 1: Biopharmaceutical classification system class II to IV drugs employing SEDDS.**

SEDDS formulations are distinguished by their tiny droplet size, mucus penetration, and protease resistance every one of which, help to overcome problems encountered during the presidency of a medicament.[7,8] Traditional formulations for SEDDS are often manufactured as liquid pre-concentrate forms, allowing the drug molecule to be used in a little amount in a small number of different dose types while also providing stability, storage, and transport benefits. in addition for dealing with problems.

Solid dosage forms, the opposite is true, are easier to utilize, leading in improvedpatient compliance in the first place. The SEDDS (Self-Emulsifying Drug Delivery System) is now gaining popularity. SEDDS have an isotropic distribution. Combinations of co-solvents/surfactants with a hydrophilic solvent or many with the unique capacity to create oil-in-water (o/w) fine microemulsions after light In aqueous mediums GI, for example fluids, Dilution and agitation are required.

Self-emulsifying mechanisms for delivering drugs are lipid-based formulation techniques, and their potential to provide a major solution to the solubility challenges that most antihypertensive medicines confront, including their simplicity of manufacture, make them a popular alternative. Physical Spray-drug be applied to convert SEDDS formulations into solid dosages together with capsule filling types of age.[4,9,10]

These types of age methods then been employed on many SEDDS come in several forms. Formulations, particularly when anticancer medications like docetaxel,[11] curcumin,[12] tacrolimus,[13] and sirolimus[14] are included, in addition anti- inflammatory pharmaceuticals like dexibuprofen[15] and flurbiprofen.[16] The excipients utilised in the growth SEDDS that are solid are the same as those used in liquid SEDDS; however, extra excipients should be chosen in the evolution of according to the situation solidification procedure.

**SNEDDS (Self-Nano Drug Delivery Emulsifier System):** SEDDS produces nano- emulsions. Regardless of production technique, They're a mixed bag. Two non-mixable liquids (oil-in-water [O/W] or water-in-oil [W/O]) mixed together. with the dimensions of an average droplet a on a nanometric scale (usually 20-200 nm).




**Fig. no. 2: Mechanisms of self emulsifying drug delivery system.**

**Table no. 1: Differences and Similarity between SEDDS and SMEDDS.**

| Sedds | Smedds |
|---|---|
| **Difference** | |
| 1. A simple binary formulation containing the drug and a lipidic surfactant and oil capable of self-emulsifying when in contact with gif. | 1. They are made up of the drug compound, a surfactant, a co-surfactant, and oil for the lipid phase. |
| 2. The dispersion's lipid droplet size ranges from 200nm to 5m, providing a large surface area absorption and a turbid appearance. | 2. Lipid droplet size in dispersion ranges from less than 200 nm and appears optically clear to translucent. |
| 3. Sedds are thermodynamically unstable in water or physiological fluids. | 3. Smedds are thermodynamically stable in physiological fluids or water. |
| 4. The oil concentration ranges between 40-80%. | 4. Concentration of oil <20% |
| 5. Sedds optimization requires the use of a ternary phase diagram. | 5. Smedds optimization requires a pseudo ternary phase diagram. |
| **Similarities** | |
| In contact with gif, form a fine oil-in-water dispersion. | |

**Seed benefits[15]**

1. Rapid onset of action.
2. Drug dose reduction
3. Manufacturing and Scale-up Ease
4. Increased bioavailability in the mouth.
5. Increased oral bioavailability allows for dosage decrease.
6. More consistent medication absorption temporal patterns.
7. Drugs are targeted to a specific absorption window in the in the digestivetract.
8. Drug(s) protection against the gut's hazardous environment.Controlling delivery profiles is number.

**Disadvantages of sedds[3]**

1. Due to the to the top content, there is a risk of drug instabilities.
2. In self-emulsifying formulations, the increased surfactant concentration irritates the gastro-intestinal tract.
3. Before the strength of this in vitro study model can be assessed, It has to be further developed and validated.

**Sedds properties[4]**

1. They are able to self-emulsify swiftly in the fluids of the gastrointestinal tract and create a thin o/w emulsion under the effect o mildly agitated produced via peristaltic mechanisms motions of the gastro-intestinal tract.
2. Drugs (hydrophobic or hydrophilic) can be successfully incorporated into the oil surfactant mixture.
3. They are suitable for both liquid and solid dose forms.
4. In comparison to traditional dosage forms, they require a lower medication dose.

**Composition of sedds**

SEDDS are diverse collection of materials. The following elements must be considered.

1. The nature of the oil–surfactant combination
2. The concentration of surfactant
3. The self–emulsification temperature

**Oils:** Oils: Oils have the ability to solubilize. a precise amount The most common type of lipophilic medicine is essential since it's an excipient it aids self-emulsification and increases the proportion of lipophilic medication delivered via the lymphatic system of the intestines, resulting in increased GI absorption. SEDDSs were created using oils containing long-chain triglycerides and medium- chain triglycerides varying degrees of saturation. Because of their formula, Vegetable oils that have been changed or hydrolyzed have made a contribution. significantly to the success of SEDDSs. Novel semi synthetic medium-chain triglyceride oils contain surfactant qualities and are frequently used to replace traditional medium chain triglyceride oils.

**Surfactant:** Cremophore, Tween, Labrasol, Labrafac CM 10, and other nonionic surfactants with a high hydrophilic–lipophilic balance (HLB) value are employed in the development of SEDDSs . In order to generate a stable SEDDS, the surfactantstrength typically varies from 30–60% w/w in the formulation. The hydrophilicity and HLB of surfactants are high.

**Cosurfactant/Co-solubilizers:** The creation of an optimal SMEDDS necessitates rather Surfactant concentrationsthat are too high (usually greater than 30% w/w), yet this produces GI discomfort. As a result, co surfactant is utilized to lower surfactant concentration. Combined with the co-role surfactant's is to lessen is to reduce interfacial tension to an extremely low, even transiently negative value. At this point, the contact expands to create finely distributed droplets, which then absorb additional surfactant and/or co-surfactant until their bulk condition is reduced enough to restore positive interfacial tension.

The micro emulsions are created by a process known as "spontaneous emulsification." Organic solvents like as ethanol, propylene glycol (PG), polyethylene glycol (PEG), and others that are appropriate for absorption by mouth may aid in the dissolution of significant doses of

either. Although alcohol- free self-emulsifying micro emulsions have been documented in the literature, the hydrophilic surfactant or drug in the lipid base can operate as a co-surfactant in Drug delivery methods that self-emulsify. Capyrol 90, Capmul, lauroglycol, and diethylene glycol monoethyl ether are examples of cosurfactants/cosolvents (transcutol).

**SEDDSs are created by combining two or more SEDDSs.**

For encapsulating in hard or soft gelatin or mixes, a variety of combinations can be created that disperse to produce tiny colloidal particles emulsions, Excipients are available in a wide range of liquid or waxy forms, ranging from oils to biological lipids, hydrophobic and hydrophilic surfactants, and more. Water soluble cosurfactant/cosolvents.

**Table no. 2: Examples of oils, Surfactants and Co-surfactants**.

| Oils | Surfactants | Co-surfactants/Co-solvent |
|---|---|---|
| Cotton seed oil | Polysorbate 20 (Tween 20) | Span 20 |
| Soybean oil | Polysorbate 80 (Tween 80) | Span 80 |
| Corn | D-alpha Tocopheryl polyethylene glycol 1000 succinate (TPGS) | Capryol 90 |
| Sunflower oil | Polyoxy-35-castor oil (Cremophor RH40) | Lauroglycol |
| Castor oil | Polyoxy-40- hydrogenated castor oil (Cremophor RH40) | Transcutol |
| Sesame oil | Labrasol | Capmul |
| Peanut oil | | Ethanol |
| Labrafac oil | | Polypylene glycol |
| Labrafil | | Polyethylene glycol |

**Mechanism of self-emulsification**

Self-emulsification happens when the entropy shift favoring dispersion is larger than the energy necessary to expand the surface area of the dispersion, according to Reiss[16]. energy that is available for free a traditional. The energy has a direct effect on emulsion. necessary to produce between the oil and the water, phases, and may be expressed as follows:

$$DG = S N_i p r_i 2s$$

Where DG denotes the process's free energy(Ignoring mi's free energy) N is the number of droplets in the mixture), radius, and s denotes the interfacial energy. There are two stages of an Emulsions have a tendency to separate. over time, reducing the interfacial area, and the emulsion is then stabilized by emulsifying agents, which produce a monolayer of emulsion droplets, decreasing the energy transfer between the two surfaces, and preventing coalescence.

**Biopharmaceutical aspects**

The capacity of lipids and/or food to improve the bioavailability of weakly water-soluble medicines has been well examined, and interested readers shouldconsult these publications for more information.[19,20] Although the exact processes are unknown, it is widely assumed that lipids can increase bioavailability through a number of methods, including.

**Gastric alterations (Reduction) in gastric transit:** Delivery towards the absorption location and lengthening the dissolution time.[21]

**Increased solubility of effective luminal drugs:** Lipids are found in the body . The presence of lipids in the stomach and intestines promotes the production of bile salts and biliary lipids produced by the body. Two types of biles salts such ass phospholipids and cholesterol, resulting in the emergence of BS/PL/CH mixed micelles in the intestines and increase in the GI tract solubilization capacity.

**Stimulation of intestinal lymphatic transports:** Lipids may boost the extent of lymphatic transportation and increases bioavailability directly or indirectly by reducing first-pass metabolism[22,23] for highly lipophilic medicines

**Shifts in the biochemical barrier function of the GI tract:** Certain surfactants and lipids as suggested by the p-glycoprotein influx pump, may limit the degree of electrocyte-based metabolism[24,25] and may also have a calming effect and the activity of intestinal efflux transporter.




**Fig. no. 2: Physiological pathways that result in reduced drug bioavailability via oral conventional dosage form.**

**Changes in the GI tract's physical barrier function:** Permeability enhancing effect have been demonstrated in lipid digestions, different lipids combinations products, and surfactants.[26,27] Passive intestinal permeability, on the other hand, regard to exist a considerable obstacle Bioavailability refers to the capacity of a substance to be absorbed into the body. Most poorly water-soluble and especially lipophilic, medicines.

**Effects of oil on absorption:** with gentle agitation, such composition generates an oil -in water emulsion, which may gastrointestinal motility is a term used to described the movement of food through the digestive tract. The plasma level -time profile is a graph that shows how plasma level changes over time .also more repeatable with a SEDDS. Various physiological processes, such as enhanced gastrointestinal motility, increased bile flow and drug solubilization, and improved mucosal permeability.

**Characterization of sedds**

Visual examination is the most common method of self-emulsification assessment The pace at which emulsification, droplet size distribution, and turbidity measurements might all be used to determine the effectiveness of self-emulsification.

1. **Visual assessment:** This might provide vital information just on mixture's ability to self-emulsify and micro emulsify as well as the resulting dispersion properties, that results.
2. **Turbidity measurement:** This is to determine if the dispersion reaches a point of equilibrium quickly and in a repeatable time to detect efficient self-emulsification.
3. **Droplet size and Particle size measurements:** The size of emulsion droplets is determined using photon correlation spectroscopy (PCS), dynamic light scattering (DLS), or Laser Diffraction Techniques. Particle Size Analyzer, Mastersizer, Zetasizer, and other instruments capable of measuring sizes between 10 and 5000 nm are available for particle size measurement.
4. **Zeta potential measurement:** This is used to determine the droplet's charge. Because Fatty acids that aren't bound together are present in typical The charge on an oil droplet is SEDDSs. is negative.
6. **Determination on Self-emulsification time, dispersibility:** Self-emulsification time, dispersibility, appearance, and flowability were measured and evaluated using the methodology given by H. Shen et al. for formulation grading.

**REFERENCE**


1. Mistry R, Sheth N S: Self emulsifying drug delivery system. International Journal of Pharmacy and Pharmaceutical Sciences, 2011; 3(2): 23-28.
2. Chouksey r, et al: Preparation and evaluation of the self-emulsifying drug delivery system containing atorvastatin HMGCOA inhibiter. International Journal of Pharmacy and Pharmaceutical Sciences, 2011; 3(3): 147-152.
3. Shukla J B, et al: Self micro emulsifying drug delivery system pharma science monitor. Journal of Pharmacy and Pharmaceutical Sciences, 2010; 1(2): 13-33.
4. Sapraa K, et al: Self Emulsifying Drug Delivery System: A Tool in Solubility Enhancement of Poorly Soluble Drugs; Indo Global Journal of Pharmaceutical Sciences, 2012; 2(3): 313-332.
5. Patel P A, et al: Self Emulsifying Drug Delivery System: A Review. Research Journal of Pharmacy and Technology, 2008; 1(4): 313-323.
6. Revathi S, Dhana Raju MD: Self-emulsifying drug delivery system: A review. World Journal of Pharmacy and Pharmaceutical Sciences, 2013; 2(1): 89-107.
7. Sunitha R, Satya sireesha D and Aparna M V: Novel self-emulsifying drug delivery system- an approach to enhance bioavailability of poorly water-soluble drugs. International Journal of Research in Pharmacy and Chemistry, 2011; 1(4): 828-838.
8. Singh G, et al: Self-emulsifying drug delivery systems (SEEDS): An approach for delivery of poorly water-soluble drug. International Journal of Pharmacy & Life Sciences, 2012; 3(9): 1991-1996.
9. Kumar A, Sharma S, Kamble R, Self emulsifying drug delivery system (sedds): future aspects, Int J of

Pharmacy and Pharma Sci, 2010; 2, 4: 7-13.
10. Garrigue JS, Benita S, Self-emulsifying oral lipid based formulation for improved delivery of lipophilic drugs, Application of particulate delivery systems, 3: 429-480.
11. Wakerly MG, Pouton CW, Meakin BJ. Evaluation of the self-emulsifying performance of a non-ionic surfactant- vegetable oil mixture, J Pharm Pharmacol. 1985; 6-39.
12. Charman SA, Charman WN, Rogge MC, Wilson TD, Dutko FJ, Pouton CW. Self-emulsifying drug delivery systems: formulation and biopharmaceutical evaluation of an investigational lipophilic compound. Pharm. Res, 1992; 9, 87–93.
13. Constantinides PP. Lipid microemulsion for improving drug dissolution and oral absorption Physical and biopharmaceutical aspects. J Pharm Res, 12, 1561- 1572.
14. Hauss DJ, Fogal SE. Lipid-based delivery systems for improving the bioavailability and lymphatic transport of poorly water soluble LTB4 inhibitors, J Pharm Sci, 1998; 87: 164-169.
15. Mittal P, Seth N, Rana AC: Self-microemulsifying drug delivery system(SMEDDS) : An alternative approach for hydrophobic drugs, International Journal of Natural product science, 2012; 1: 80.
16. Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J Pharm Toxicology, 44: 235–249.
17. Reddy IK, Kommuru TR, Gurley B, Khan MA. Self-emulsifying drug delivery systems (SEDDS) of coenzyme Q10 formulation development and bioavailability assessment, Int J Pharm, 2001; 212: 233–246.
18. B. Williams, G. Mancia, W. Spiering, et al., ESC/ESH Guidelines for the management of arterial hypertension, Eur. Heart J, 2018; 39 (33): 3021–3104.
19. A.I. Goldberg, M.C. Dunlay, C.S. Sweet, Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipne ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension, Am. J. Cardiol, 1995; 75 (12): 793–795.
20. G. Chongkai, H. Huiqiu, L. Ning, et al., Osmotic Pump Controlled Release Tablet of Losartan Potassium and Hydrochlorothiazide Solid Dispersion or Inclusion Compound, CN103006566 A, 2013. Drugbank, Losartan potassium, May 26, https://www.drugbank.ca/salts/DBS ALT000112, 2020.
21. Groves MJ, Mustafa RMA, Carless JE. Phase studies of mixed phosphate surfactants n-hexane and water. J Pharm Pharmacol, 1974; 26: 616-623.
22. Rang MJ, Miller CA. Spontaneous emulsification of oils containing hydrocarbon non-ionic surfactant and oleyl alcohol. J Colloids Interface Sci, 1999; 209: 179-192.
23. Pouton CW, Wakerly MG, Meakin BJ. Self-emulsifying systems for oral delivery of drugs. Pro Int Symp Control release Bioact Mater, 1987; 14: 113-114.
24. Gershanik T, Benita S. Self-dispersing lipid formulation for improving oral absorption of lipophilic drugs. Eur J Pharm and Biopharm. 2000; 50: 179-188.
25. Pouton CW. Effects of inclusion of a model drug on the performance of self-emulsifying formulations. J Pharm Pharmacol, 1985; 37.
26. Chanana GD, Sheth BB. Particle size reduction of emulsions by formulation design effect of oil and surfactant concentration PDA. J Pharm Sci Technol, 1995; 49: 71-76.
27. Kumar S, Gupta S and Sharma P K: Self-Emulsifying Drug Delivery Systems (SEDDS) for oral delivery of lipid-based formulations. African Journal of Basic & Applied Science, 2012; 4 (1): 07-11.
28. Nigade P M, Patil S, Tiwari S S: Self Emulsifying drug delivery system (SEDDS): A review. International Journal of Pharmacy and Biological Sciences, 2012; 2(2): 42-52.
29. Sharma V, et al: SMEDDS: A novel approach for lipophilic drugs. International Journal of Pharmaceutical Science and Research, 2012; 3(8): 2441-2450.
30. Bhargava P, Bhargava S, and Daharwal S J: Self-emulsifying drug delivery System: an approach to improve the solubility of poorly water-soluble drugs. Advance Research in Pharmaceuticals and Biologicals, 2011; 1(1): 1-9.
31. Christopher Porter J H, et al: Enhancing intestinal drug solubilization using lipid-based delivery systems. Advanced Drug Delivery Reviews, 2008; 60: 673–691.
32. Kommuru TR, Gurley B, Khan MA, Reddy IK. Self-emulsifying drug delivery systems (SEDDS) of coenzyme Q10: formulation development and bioavailability assessment. Int J Pharm, 2001; 212: 233-46.
33. Aungst BJ. Novel formulation strategies for improving oral bioavailability of drugs with poor membrane permeation orpre systemic metabolism. J Pharm Sci, 1993; 82: 979-87.
34. Humberstone AJ, Charman WN. Lipid-based vehicles for theoral delivery of poorly water solubledrugs. Adv Drug Del Rev, 1997; 25: 103-28.
35. Pouton CW. Formulation of self-emulsifying drug delivery systems. Adv Drug Del Rev, 1997; 25: 47-58.
36. Gursoy RN, Benita S. Self-emulsifying drug delivery systems(SEDDS) for improved oral delivery of lipophilic drugs. Biomed Pharmacother, 2004; 58: 173-82.
37. Gershanik T, Benita S. Self-dispersing lipid formulations for improving oral absorption of lipophilic drugs. Eur J Pharm Biopharm, 2000; 50: 179-88.
38. Craig DQM, Lievens HSR, Pitt K G, Storey DE. An

investigation into physico-chemical properties of self- emulsifying system susing low frequency dielectric spectroscopy, surface tension measurements and particle size analysis. Int J Pharm, 1993; 96: 147-55.

39. R.W. Bussmann, N.Y. Paniagua, C. Romero, R.E. Hart, Astonishing diversity-the medicinal plant markets of Bogot´a, Colombia, J. Ethnobiol. Ethnomed, 2018; 14 (43): 1–47. https://doi.org/10.1186/s13002-018-0241-8.
40. M.N. Marroquín, S.M. Cruz, A. C´aceres, Antioxidant activity and phenolic compounds in three species of Passifloraceae (Passiflora edulis, P. incarnata, P. ligularis) from Guatemala, Acta Hortic, 2012; 964: 93–98, https://doi.org/ 10.17660/ActaHortic.2012.964.11
41. S.A.C. Navarro, A.P.S. Aldana, F.F. Longas, Potential antioxidante y antimicrobiano de extractos acuosos e hidroalcoh´olicos de granadilla (Passiflora ligularis), Acta Agron, 2014; 63 (3): 204–211, https://doi.org/10.15446/acag.v63n3.41976.
42. S. Kannan, B. Parimala Devi, B. Jayakar, Antibacterial activity of Passiflora ligularis, Int. J. Chem. Sci, 2011; 9 (1): 393–396. https://www.cabdirect.org/cabdirect/a bstract/20113186765
43. P. Sepúlveda, S. Echeverry, G. Costa, M. Arag´on, Passiflora ligularis leaf ultrasound-assisted extraction in the optimization of flavonoid content and enhancement of hypoglycemic activity, J. Appl. Pharmaceut. Sci, 2020; 10: 86–94. https://doi.org/ 10.7324/japs.2020.10810.
44. D. Rey, T.A. Fernandes, P.M. Sulis, R. Gonçalves, M. Sepúlveda R, M.J. Silva Frederico, M. Arag´on, L.F. Ospina, G.M. Costa, F.R.M.B. Silva, Cellular target of isoquercetin from Passiflora ligularis Juss for glucose uptake in rat soleus muscle, Chem. Biol. Interact, 2020; 330: 109198. https://doi.org/10.1016/j. cbi.2020.109198. D. Rey, P. Miranda Sulis, T. Alves Fernandes, R. Gonçalves, M.J. Silva Frederico, G. M. Costa, M. Arag´on, L.F. Ospina, F.R. Mena Barreto Silva, Astragalin augments basal calcium influx and insulin secretion in rat pancreatic islets, Cell Calcium, 2019; 80: 56–62. https://doi.org/10.1016/j.ceca.2019.03.009
45. G. Monz´on Daza, A.M. Meneses Macías, Carolina Forero, J. Rodríguez, M. Arag´on, C. Jim´enez, F. Ramos, C. Leonardo, Identification of α-amylase and α-glucosidase inhibitors and Ligularoside A, a new triterpenoid saponin from Passiflora ligularis Juss (Sweet Granadilla) leaves, by a nuclear magnetic resonance-based metabolomic study, J. Agric. Food Chem, 2021; 69: 2919–2931. https://doi.org/ 10.1021/acs.jafc.0c07850.
46. S.H. Thilakarathna, H.P. Vasantha Rupasinghe, Flavonoid bioavailability and attempts for bioavailability enhancement, Nutrients, 2013; 5: 3367–3387. https:// doi.org/10.3390/nu5093367.